Humoral response against myelin associated glycoprotein reflects oligodendroglial degeneration in Parkinson’s disease
Ewa Papuć 1, Barbara Wilczyńska 2, Konrad Rejdak 1 1 - Department of Neurology, Medical University of Lublin, Poland 2 - Chair and Department of Clinical Immunology, Medical University of Lublin, Poland Ann Agric Environ Med 2016; 23 (2): ICID: 1203998 Article type: Short communication
Identification of disease-specific diagnostic and prognostic biomarkers which would enable early detection and follow-up of Parkinson’s disease (PD) is a crucial problem. Recently, we confirmed the presence of adaptive immune response against different glial-derived antigens in PD. Objective. The aim of the study was to assess humoral response against myelin-associated glycoprotein (MAG) on a larger group of PD patients. IgM autoantibodies against MAG were measured by an ELISA system in 66 PD patients and 66 control subjects. Results. The study confirmed a significantly increased production of anti-MAG IgM antibodies in parkinsonian patients (p<0.05). No correlations were found between anti-MAG IgM antibody titers and disease severity measured on the Hoehn-Yahr scale, MMSE or age of PD onset (p>0.05). The results provide evidence for activation of humoral response against MAG in PD patients, but argue against the utility of anti-MAG antibodies as biomarkers of disease severity. The results additionally indicate the potential protective role of autoimmunity in maintaining the body’s homeostasis, which may involve the clearance of abnormal proteins. Further studies are necessary to confirm the role of anti-MAG antibodies as biomarkers of PD, especially in relation to other neurodegenerative disorders.
DOI: 10.5604/12321966.1203998 PMID 27294656 - click here to show this article in PubMed